#United States #New York #Securities Fraud #Pomerantz LLP #Neogen Corporation

Overview of the Investigation

On November 5, 2026, it was announced that the Pomerantz Law Firm is actively investigating potential claims from investors of Neogen Corporation (NASDAQ: NEOG). This investigation arises from alarming reports related to the company’s products, particularly concerning a veterinary product linked to severe health risks. The law firm urges affected investors to reach out for further information and possible legal recourse.

FDA Concerns

The catalyst for the investigation was a confirmation from the U.S. Food and Drug Administration (FDA) on September 29, 2026. The FDA revealed that it had issued a warning letter to Neogen regarding their veterinary wound care product—Neogen Vet HYCOAT, which is marketed as a sterile solution. The investigation highlighted a troubling correlation between the product and serious infections that led to the death of at least 20 horses. This incident marks a significant concern, being the most substantial number of deaths associated with quality defects in an FDA-regulated veterinary product. Additionally, it stands as the highest toll among any animal species due to microbiological contamination linked to what was marketed as a sterile product.

Upon the distribution of this news, the market reacted — Neogen’s share price plummeted by $0.99, translating to a 7.22% decrease, closing at $12.73 on the same day.

About Pomerantz LLP

Pomerantz LLP, renowned for its expertise in class action litigation, particularly in securities fraud and corporate misconduct, has been a pivotal entity in protecting investors’ rights for over 85 years. Founded by the late Abraham L. Pomerantz, the firm has a rich history of significant recoveries for their clients in securities-related disputes. With offices across various cities globally, Pomerantz continues to advocate for victims of corporate malfeasance.

What This Means for Investors

Investors in Neogen Corporation should closely monitor this ongoing investigation as it may have implications regarding potential financial recoveries through class action lawsuits. Those who believe they may be impacted by the issues surrounding Neogen's products should consider reaching out to Pomerantz LLP for guidance. Danielle Peyton, from the firm, is the advised point of contact for inquiries, reachable at [email protected], or by calling 646-581-9980, ext. 7980.

This situation serves as a critical reminder of the necessity for diligence from both shareholders and regulatory agencies in maintaining product safety and business integrity within the competitive field of veterinary medicine. As investigations unfold, updates will be essential for all stakeholders involved with Neogen Corporation.